Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KRAS G13D antibody - Oblique Therapeutics

Next Previous
Search
Drug Profile

KRAS G13D antibody - Oblique Therapeutics

Alternative Names: aKRAS - Oblique Therapeutics; Anti-G13D mAbs - Oblique Therapeutics; aTRPA1 - Oblique Therapeutics; aTRPV1 - Oblique Therapeutics

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oblique Therapeutics
  • Class Analgesics; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer
  • No development reported Pain

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in Pain in Sweden (Parenteral)
  • 17 Jan 2023 Preclinical development for Pain is underway in Sweden (Parenteral) (Oblique Therapeutics pipeline, January 2023)
  • 17 Jan 2023 Oblique Therapeutics plans a phase I trial for Cancer in 2027 (Oblique Therapeutics pipeline, January 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top